Lemtrada - Clinical Immunology

PARIS (Reuters) - French drugmaker Sanofi said on Saturday that its experimental multiple sclerosis drug Lemtrada worked better than an older drug sold by competitor Merck KGaA at keeping patients free from relapses.New data from a late-stage trial showed that 78 percent ...